69738-33-6

Upstream product

• 69738-32-5 1-[(2-methanesulfonyloxy)ethyl]-2,3-dimethoxybenzene 
• 90-53-9 2,3-dimethoxyphenylacetic acid 
• 13335-51-8 2-(2,3-dimethoxyphenyl)ethan-1-ol 

Downstream Products

• 1194473-25-0 C₁₄H₂₃O₅P 

Relevant academic research and scientific papers

NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY

The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particuarl embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 μM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 μM (or 3.7-19 μg/mL).